These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19067906)

  • 1. Cyclic pamidronate treatment in Bruck syndrome: proposal of a new modality of treatment.
    Andiran N; Alikasifoglu A; Alanay Y; Yordam N
    Pediatr Int; 2008 Dec; 50(6):836-8. PubMed ID: 19067906
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta.
    Eto S; Hada S; Fukuhara R; Nishimura G; Takagi M
    Pediatr Int; 2018 May; 60(5):485-486. PubMed ID: 29700899
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
    Yamashita S
    Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle weakness as presenting symptom of osteogenesis imperfecta.
    Boot AM; de Coo RF; Pals G; de Muinck Keizer-Schrama SM
    Eur J Pediatr; 2006 Jun; 165(6):392-4. PubMed ID: 16534588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
    Choi JH; Shin YL; Yoo HW
    J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first case of Bruck syndrome associated with gastroschisis.
    Afşarlar ÇE; Peltek-Kendirci HN; Erdoğan D; Özgüner İF; Çavuşoğlu YH; Karaman A; Çetinkaya S
    Turk J Pediatr; 2013; 55(6):651-4. PubMed ID: 24577988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two doses of pamidronate in infants with osteogenesis imperfecta.
    Senthilnathan S; Walker E; Bishop NJ
    Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hearing is not affected by diphosphonates in osteogenesis imperfecta. Retrospective study of 42 medical records].
    Brodd I; Hederstierna C; Sääf M; Hultcrantz M
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1906-9. PubMed ID: 22111228
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
    Bajpai A; Kabra M; Gupta N; Sharda S; Ghosh M
    J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brainstem and cerebellar hypoplasia associated with osteogenesis imperfecta type-5.
    Syamlal S; Shine S; Kunju M
    J Postgrad Med; 2006; 52(2):152-3. PubMed ID: 16679688
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report.
    Olson JA
    J Pediatr Rehabil Med; 2014; 7(2):155-8. PubMed ID: 25096867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.